Clinical characteristics and outcomes of previously untreated patients with adult onset T-ALL and T-lymphoblastic lymphoma (T-LL) with Hyper-CVAD based regimens

Samankaltaisia teoksia

• TP53 Mutation Does Not Confer a Poor Outcome in Adult ALL Treated with Frontline Hyper-CVAD-based Regimens
  Tekijä: Kanagal-Shamanna, Rashmi, et al.
  Julkaistu: (2017)
• Hyper-CVAD + ponatinib vs. hyper-CVAD + dasatinib as frontline therapy for Ph-positive ALL: a propensity score analysis
  Tekijä: Sasaki, Koji, et al.
  Julkaistu: (2016)
• First Report of a Phase II Prospective Study of Combination of Hyper-CVAD with Ponatinib in Frontline Therapy of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
  Tekijä: Jabbour, Elias, et al.
  Julkaistu: (2015)
• Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
  Tekijä: Daver, Naval, et al.
  Julkaistu: (2015)
• Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab vs. Standard Intensive Chemotherapy (hyper-CVAD) as Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: a Propensity Score Analysis
  Tekijä: Jabbour, Elias, et al.
  Julkaistu: (2019)